
Anixa Biosciences Inc — Investor Relations & Filings
Anixa Biosciences Inc. is a clinical-stage biotechnology company focused on developing therapies and vaccines for the treatment and prevention of cancer. The company's portfolio is centered on two main platforms: a therapeutics program and a vaccine program. The therapeutics portfolio features a Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy, which genetically engineers a patient's own immune cells to target and destroy solid tumors. The vaccine portfolio includes preventative and therapeutic candidates for various cancers, with a primary focus on breast and ovarian cancer, and discovery programs for lung, colon, and prostate cancer. Anixa aims to address critical unmet needs in oncology through these innovative approaches.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 8-K | 2026-03-11 | English | |
| 10-Q | 2026-03-09 | English | |
| 8-K Filing | 2026-02-09 | English | |
| 4 Filing | 2026-01-29 | English | |
| DEF 14A Filing | 2026-01-28 | English | |
| 10-K Filing | 2026-01-12 | English |
Browse filings by year
32 years- 2026 13 filings
- 2025 32 filings
- 2024 30 filings
- 2023 20 filings
- 2022 36 filings
- 2021 48 filings
- 2020 36 filings
- 2019 39 filings
- 2018 41 filings
- 2017 66 filings
- 2016 46 filings
- 2015 126 filings
- 2014 79 filings
- 2013 50 filings
- 2012 43 filings
- 2011 25 filings
- 2010 32 filings
- 2009 16 filings
- 2008 15 filings
- 2007 21 filings
- 2006 19 filings
- 2005 23 filings
- 2004 27 filings
- 2003 14 filings
- 2002 7 filings
- 2001 9 filings
- 2000 6 filings
- 1999 8 filings
- 1998 5 filings
- 1997 7 filings
- 1996 12 filings
- 1995 7 filings
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
13 filings
| |||||
| 46076185 | 8-K | 2026-03-11 | English | ||
| 46076247 | 10-Q | 2026-03-09 | English | ||
| 18168263 | 8-K Filing | 2026-02-09 | English | ||
| 18168267 | 4 Filing | 2026-01-29 | English | ||
| 18168260 | DEF 14A Filing | 2026-01-28 | English | ||
| 18168268 | 10-K Filing | 2026-01-12 | English | ||
| 18168261 | S-8 Filing | 2026-01-12 | English | ||
| 18168271 | SCHEDULE 13D/A Filing | 2026-01-06 | English | ||
| 18168270 | 4 Filing | 2026-01-06 | English | ||
| 18168266 | 4 Filing | 2026-01-06 | English | ||
| 18168264 | 4 Filing | 2026-01-06 | English | ||
| 18168262 | 4 Filing | 2026-01-06 | English | ||
| 18168258 | 4 Filing | 2026-01-06 | English | ||
|
2025
2 filings
| |||||
| 18168265 | 4 Filing | 2025-12-16 | English | ||
| 18168269 | 8-K Filing | 2025-12-12 | English | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
KIM FOREST
Offers integrated precision medicine and molecular diagnost…
|
6645 | TW | Professional, scientific and te… |
|
Kura Oncology, Inc.
Clinical-stage biopharma company developing precision medic…
|
KURA | US | Professional, scientific and te… |
|
LAB Research Inc.
Global non-clinical CRO specializing in contract research, …
|
LRI | CA | Professional, scientific and te… |
|
Laekna, Inc.
Clinical-stage biotech developing novel therapies for oncol…
|
2105 | HK | Professional, scientific and te… |
|
Larimar Therapeutics, Inc.
A clinical-stage biotech developing treatments for complex …
|
LRMR | US | Professional, scientific and te… |
|
Lexaria Bioscience Corp.
A biotech company with a patented platform to improve oral …
|
LEXX | US | Professional, scientific and te… |
|
LigaChem Biosciences Inc.
Clinical-stage biopharma developing ADCs, immuno-oncology d…
|
141080 | KR | Professional, scientific and te… |
|
Linical Co., Ltd.
A global CRO providing a full spectrum of drug development …
|
2183 | JP | Professional, scientific and te… |
|
Lipigon Pharmaceuticals AB
A clinical-stage company developing therapeutics for lipid-…
|
LPGO | SE | Professional, scientific and te… |
|
Lipum AB
Clinical-stage biopharma developing novel treatments for ch…
|
LIPUM | SE | Professional, scientific and te… |
Anixa Biosciences Inc via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34117/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34117 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34117 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34117 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34117}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Anixa Biosciences Inc (id: 34117)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.